✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Capmatinib hydrochlorideis the generic ingredient in one branded drug marketed by Novartis Pharm and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Capmatinib hydrochloride has one hundred and sixty-five patent family members in forty-two countries.
One supplier is listed for this compound.
Recent Clinical Trials for capmatinib hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
|Southwest Oncology Group||Phase 2|
|National Cancer Institute (NCI)||Phase 2|
|Timothy Burns||Phase 2|
Pharmacology for capmatinib hydrochloride
|Country||Patent Number||Title||Estimated Expiration|
|Slovenia||2099447||See Plans and Pricing|
|South Korea||20090094299||키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘 (IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS)||See Plans and Pricing|
|Norway||20200077||Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer||See Plans and Pricing|
|Taiwan||200835481||Imidazotriazines and imidazopyrimidines as kinase inhibitors||See Plans and Pricing|
|Ecuador||SP099400||IMIDAZOTRIAZINAS E IMIDAZOPIRIMIDINAS COMO INHIBIDORES DE CINASA||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|2099447||CA 2022 00053||Denmark||See Plans and Pricing||PRODUCT NAME: CAPMATINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/22/1650 20220621|
|2099447||PA2022527||Lithuania||See Plans and Pricing||PRODUCT NAME: KAPMATINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/22/1650 20220620|
|2099447||C02099447/01||Switzerland||See Plans and Pricing||PRODUCT NAME: CAPMATINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67648 26.04.2021|
|2099447||301209||Netherlands||See Plans and Pricing||PRODUCT NAME: CAPMATINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/22/1650 20220621|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.